CD38抗体达雷妥尤单抗治疗肾移植后微血管炎症的多中心注册研究
该回顾性多中心注册研究纳入70例肾移植后出现微血管炎症(MVI)的患者,其中59例为抗体介导排斥反应(AMR),11例为DSA和C4d阴性MVI。达雷妥尤单抗治疗后eGFR由诊断前一年的-1.6 ml/min/1.73m2/月转为+0.3 ml/min/1.73m2/月,白蛋白尿和dd-cfDNA早期下降,DSA变化异质。提示达雷妥尤单抗可能稳定肾功能。
要点
- 达雷妥尤单抗治疗肾移植后MVI,eGFR变化由-1.6转为+0.3 ml/min/1.73m2/月。
- 白蛋白尿和dd-cfDNA早期下降,DSA变化异质。
- 随访期间6例患者移植物丢失,剂量和疗程对结局无显著影响。
核心结论
- 初步数据显示达雷妥尤单抗可稳定肾移植后MVI患者的肾功能。
研究设计与样本
- 回顾性多中心注册研究,纳入70例肾移植后MVI患者,其中59例AMR,11例DSA和C4d阴性MVI。
- 收集中位移植至MVI诊断36个月、诊断至达雷妥尤单抗治疗中位1.6个月的数据。
主要发现
- eGFR变化由诊断前一年的-1.6 ml/min/1.73m2/月转为治疗后的+0.3 ml/min/1.73m2/月。
- 随访期间6例患者移植物丢失。
- 白蛋白尿和dd-cfDNA中位水平治疗早期下降,DSA变化异质。
- 达雷妥尤单抗剂量数和治疗时长对结局无显著影响。
临床怎么用
- 对肾移植后MVI患者,达雷妥尤单抗可能作为稳定肾功能的治疗选择。
- 治疗期间需监测eGFR、白蛋白尿、dd-cfDNA和DSA动态变化。
局限性
- 回顾性研究设计,样本量有限,结论需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Microvascular inflammation (MVI) on kidney biopsy is associated with reduced graft survival following kidney transplantation (KT). CD38-targeting regimens, including the monoclonal antibody daratumumab, have recently emerged as a promising therapeutic strategy to counteract MVI and stabilize graft function. METHODS: Here, we retrospectively collected data on eGFR, albuminuria, kidney allograft pathology, donor specific antibodies (DSA) and donor-derived cell-free DNA (dd-cfDNA) levels from 70 KT patients both prior to and after initiation of daratumumab treatment. Safety signals were also documented. RESULTS: The study cohort consisted of 59 patients diagnosed with antibody mediated rejection (AMR) and 11 patients showing DSA- and C4d-negative MVI. Median time between transplantation and diagnosis of MVI was 36 months. Daratumumab treatment was initiated at a median of 1.6 months following diagnosis of MVI. A mixed linear model showed stabilization of eGFR from -1.6 ml/min/1.73m2/month in the year prior to the diagnosis of MVI to +0.3 ml/min/1.73m2/month after starting daratumumab. Six patients lost their graft during follow-up. Median albuminuria and dd-cfDNA levels decreased early during treatment, whereas the effect on DSA was heterogeneous. Both the number of doses and treatment duration had no measurable impact on outcome. CONCLUSIONS: Our preliminary data suggest efficacy of daratumumab in stabilizing kidney function in KT recipients with MVI.
引用
- Drasch T, Mayer KA, Böhmig GA, et al. A multicenter registry study of the CD38 antibody daratumumab for the treatment of microvascular inflammation following kidney transplantation. Kidney Int. 2026. PMID: 42492852. doi:10.1016/j.kint.2026.06.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。